Sanofi wants to earn the rep for being the hare in drug R&D. But that darn tortoise keeps sticking its head out
This is an important day for Sanofi.
For years now it’s been forced to consider deep doubts surrounding its ability to execute in R&D, with a long history of slow-footed clinical advances and a weak in-house pipeline. Its cutting-edge innovation projects came from Regeneron, which it’s been separating from. And today, during R&D day, Sanofi CEO Paul Hudson as well as R&D chief John Reed hope to leave that all behind with a forceful presentation on the pharma giant’s newfound nimbleness and capacity to build an exciting late-stage pipeline with several top projects in hand.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 84,800+ biopharma pros reading Endpoints daily — and it's free.